Publications by authors named "A Damassi"
Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study.
Giuseppe Fotia Calogero Saieva Richard Lee-Ying Anna Patrikidou Pier Vitale Nuzzo Alessandra Damassi
Clin Genitourin Cancer
October 2024
Article Synopsis
- Managing metastatic castration-resistant prostate cancer (mCRPC) in men aged 75 and older is difficult due to limited research, but common first-line treatments include abiraterone acetate plus prednisone (AA) and enzalutamide (Enza).
- A study analyzed 337 patients aged 75+ who started AA or Enza and found no significant differences in survival rates or adverse effects between those who previously used docetaxel (D) and those who only received androgen deprivation therapy (ADT).
- The results imply that elderly men with mCRPC can expect similar outcomes and side effect profiles from AA or Enza, irrespective of prior D treatment, though the study's retrospective nature
To define the prognostic significance of first-line TKI in mRCC patients receiving nivolumab. A total of 571 mRCC patients who received ≥second line nivolumab were included in this subanalysis. The correlation between prior TKI (sunitinib vs.
View Article and Find Full Text PDFArticle Synopsis
- The Meet-URO 18 study investigates metastatic renal cell carcinoma patients undergoing nivolumab treatment in two distinct groups based on their progression-free survival (PFS) times.
- The study utilizes detailed immunohistochemical analysis to assess various markers like T-lineage markers (CD3, CD4, CD8), macrophages (CD68), and PD-L1 expression in tumor samples from 113 patients, significantly expanding upon previous data.
- Results indicate that tumor tissue with lower CD4 and higher CD56 expression correlates with a more favorable antitumor response, suggesting the potential of CD56 as a biomarker for immunotherapy effectiveness.
Article Synopsis
- * The study involves detailed analysis of various immune markers in tumor samples, including T-cell markers (CD3, CD4, CD8), macrophage presence (CD68), and PD-L1 expression, now with an expanded sample size of 161 tumors from 113 patients.
- * Findings indicate that lower CD4 levels and higher CD8/CD4 ratios correlate with certain tumor characteristics, suggesting a specific T-cell subpopulation plays a role in anti-tumor response; CD56 might serve as a potential
Background: Immunotherapies exhibit peculiar cancer response patterns in contrast to chemotherapy and targeted therapy. Some patients experience disease response after initial progression or durable responses after treatment interruption. In clinical practice, immune checkpoint inhibitors may be continued after radiological progression if clinical benefit is observed.
View Article and Find Full Text PDF